Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab in Severe Uncontrolled Asthma in Brazil
NCT04228588Phase 4Unknown
- Sponsor
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
- Start
- Jan 2020
- Primary completion
- Jan 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mepolizumab in eosinophilic asthma (EA), sponsored by Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo. Primary endpoint: Saint George's Respiratory Questionnaire Total Score at 48 weeks. Status: unknown.
02
Drugs
mepolizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NCT04228588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04228588.